Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA

I

Institut für Pharmakoökonomie und Arzneimittellogistik e.V.

Status

Completed

Conditions

Atrial Fibrillation
Stroke Prophylaxis

Treatments

Drug: Novel oral anticoagulants
Drug: vitamin-k-antagonists

Study type

Observational

Funder types

Other

Identifiers

NCT02657616
NOAC001

Details and patient eligibility

About

The central questions of the study can be summarized as follows: What stroke / death rates are the result of the use of the following treatment strategies: no anticoagulation with vitamin-k-antagonists (VKAs) or novel oral anticoagulants (NOACs), anticoagulation with VKAs and anticoagulation with NOACs (all). What other thromboembolic complication rates resulting from the use of these treatment strategies? What heavy bleeding rates resulting from the defined management strategies? The analysis is based on a data set of patients with atrial fibrillation (AF)(01/01/2010 - 30/06/2014). 2010 is used as the reference period and 01/01/2011-30/06/2013 as the inclusion period. The minimum observation time per patient is 12 months. Used is a data base of the AOK PLUS as well as the AOK Baden-Württemberg and AOK Bayern. The aim of the study is to compare clinical outcomes between the different treatment strategies (frequency of events and time to first event). The influence of alternative treatment strategies is measured on the basis of three different methodological approaches: unadjusted comparison of event council and time to first event between the defined patient groups; matched-pair comparison (propensity score matching) between the different groups of patients (treatment strategies) and multivariate analysis using time to event (Cox proportional hazards model) as the dependent variable.

Enrollment

204,464 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • one inpatient or two outpatient confirmed diagnosis of atrial fibrillation in two different quarters
  • Continuously insured by the AOK PLUS, AOK Bayern or AOK Baden-Württemberg

Exclusion criteria

  • Age < 18 years
  • Maximum possible observational period < 12 months (exception: death)

Trial design

204,464 participants in 3 patient groups

No anticoagulation with VKA/NOAC
Description:
No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
Anticoagulation with vitamin-k-antagonists
Description:
The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
Treatment:
Drug: vitamin-k-antagonists
Anticoagulation with novel oral anticoagulants
Description:
The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
Treatment:
Drug: Novel oral anticoagulants

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems